Market Closed -
OTC Markets
13:53:32 2024-05-08 EDT
|
5-day change
|
1st Jan Change
|
2.6
USD
|
+7.00%
|
|
+8.33%
|
-61.40%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
365
|
399.8
|
176.3
|
52.01
|
9.964
|
3.85
|
-
|
-
|
Enterprise Value (EV)
1 |
300.4
|
302.2
|
176.3
|
52.01
|
9.964
|
3.85
|
3.85
|
3.85
|
P/E ratio
|
-4.84
x
|
-5.32
x
|
-5.19
x
|
-0.51
x
|
-0.13
x
|
-0.17
x
|
-0.72
x
|
-0.87
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
14.5
x
|
3.86
x
|
0.63
x
|
0.15
x
|
0.12
x
|
0.11
x
|
EV / Revenue
|
-
|
-
|
14.5
x
|
3.86
x
|
0.63
x
|
0.15
x
|
0.12
x
|
0.11
x
|
EV / EBITDA
|
-
|
-
|
-2,300,123
x
|
-562,561
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
817
|
1,084
|
1,133
|
1,469
|
1,479
|
1,481
|
-
|
-
|
Reference price
2 |
447.0
|
368.7
|
155.7
|
35.40
|
6.735
|
2.600
|
2.600
|
2.600
|
Announcement Date
|
20-03-13
|
21-03-09
|
22-03-10
|
23-03-17
|
24-04-08
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
12.14
|
13.48
|
15.77
|
25.22
|
32.65
|
34.36
|
EBITDA
|
-
|
-
|
-76.66
|
-92.45
|
-
|
-
|
-
|
-
|
EBIT
1 |
-68.9
|
-62.15
|
-76.94
|
-92.74
|
-71.79
|
-21.54
|
-6.221
|
-5.041
|
Operating Margin
|
-
|
-
|
-633.66%
|
-687.78%
|
-455.12%
|
-85.42%
|
-19.05%
|
-14.67%
|
Earnings before Tax (EBT)
1 |
-70.25
|
-65.05
|
-33.85
|
-96.75
|
-74.96
|
-24.84
|
-9.594
|
-8.339
|
Net income
1 |
-70.25
|
-65.05
|
-33.92
|
-96.78
|
-74.96
|
-24.84
|
-9.594
|
-8.339
|
Net margin
|
-
|
-
|
-279.34%
|
-717.71%
|
-475.26%
|
-98.49%
|
-29.38%
|
-24.27%
|
EPS
2 |
-92.40
|
-69.30
|
-30.00
|
-69.60
|
-50.78
|
-15.60
|
-3.600
|
-3.000
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-13
|
21-03-09
|
22-03-10
|
23-03-17
|
24-04-08
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
3.039
|
3.36
|
2.673
|
4.091
|
4.024
|
2.696
|
4.118
|
4.643
|
3.209
|
3.803
|
5.548
|
6.052
|
6.557
|
7.061
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-21.85
|
-20.91
|
-21.82
|
-20.08
|
-26.37
|
-24.47
|
-22.26
|
-19.98
|
-16.93
|
-12.61
|
-7.22
|
-5.147
|
-4.773
|
-4.399
|
Operating Margin
|
-719.02%
|
-622.44%
|
-816.31%
|
-490.83%
|
-655.29%
|
-907.68%
|
-540.63%
|
-430.35%
|
-527.52%
|
-331.69%
|
-130.14%
|
-85.05%
|
-72.79%
|
-62.3%
|
Earnings before Tax (EBT)
1 |
-22.21
|
-21.75
|
-22.63
|
-21.87
|
-27.11
|
-25.14
|
-22.78
|
-20.69
|
-18.03
|
-13.45
|
-7.927
|
-5.951
|
-5.641
|
-5.318
|
Net income
1 |
-22.22
|
-21.77
|
-22.64
|
-21.88
|
-27.11
|
-25.14
|
-22.78
|
-20.7
|
-18.03
|
-13.45
|
-7.927
|
-5.951
|
-5.641
|
-5.318
|
Net margin
|
-731.26%
|
-647.86%
|
-847.1%
|
-534.93%
|
-673.73%
|
-932.42%
|
-553.28%
|
-445.72%
|
-561.86%
|
-353.77%
|
-142.88%
|
-98.33%
|
-86.03%
|
-75.32%
|
EPS
2 |
-19.50
|
-19.20
|
-19.20
|
-15.30
|
-18.60
|
-16.80
|
-15.60
|
-14.10
|
-12.30
|
-
|
-5.400
|
-3.900
|
-3.600
|
-2.700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-04
|
22-03-10
|
22-05-05
|
22-08-04
|
22-11-03
|
23-03-17
|
23-05-11
|
23-08-14
|
23-11-09
|
24-04-08
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
64.6
|
97.6
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-40.5%
|
-152%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
0.48
|
0.26
|
0.23
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
1.85%
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-03-13
|
21-03-09
|
22-03-10
|
23-03-17
|
24-04-08
|
-
|
-
|
-
|
Average target price
30
USD Spread / Average Target +1,053.85% Consensus |
1st Jan change
|
Capi.
|
---|
| -61.40% | 3.6M | | +22.56% | 46.4B | | -1.51% | 41.75B | | +48.83% | 41.37B | | -3.42% | 29.71B | | +10.13% | 26.01B | | -20.44% | 19.52B | | +26.45% | 12.43B | | -0.14% | 12.18B | | -0.47% | 12.13B |
Other Biotechnology & Medical Research
|